Torbjørn Omland

Faglige interesser

• Hjertesvikt
• Koronarsykdom
• Kardiovaskulære biomarkører
• Kardiovaskulær endokrinologi
• Kardiovaskulære effekter av kreftbehandling
• Kardiovaskulær sykdom ved KOLS og obstruktiv søvnapne
• Kardiovaskulær sykdom ved depresjon

Bakgrunn

Utdanning

• 1987 Cand. Med. Universitetet i Bergen
• 1989 Diploma in Tropical Medicine (D.T.M.), University of Copenhagen, Denmark
• 1995 Educational Commission for Foreign Medical Graduates (ECFMG) Certification
• 1996 Dr. med. Universitetet i Bergen. Avhandling: Neurohumoral Activation after Acute Myocardial Infarction: Relation to Indices of Cardiac Function and Prognosis
• 1996 Program in Clinical Effectiveness, Harvard University
• 1997 Master of Public Health (M.P.H.), Harvard School of Public Health
• 2003 Basalutdanning i universitetspedagogikk, Universitetet i Oslo

Akademiske stillinger

• 1992-1995 Universitetsstipendiat, Universitetet i Bergen
• 1995-1997 Research Fellow in Medicine, Harvard University, Cambridge, MA, USA
• 2003 Professor II (hjertemedisin), Universitetet i Oslo
• 2004 Professor I (indremedisin) – Universitetet i Oslo
• 2009 Fakultetsdivisjonsleder Akerhus Universitetssykehus
• 2010-2014 Nestleder, Institutt for klinisk medisin, Universitetet i Oslo

Priser

• 1987 F. Meltzers pris (Universitetet i Bergen).
• 1995 J. William Fulbright Award.
• 1995 Caroline Musæus Aarsvolds pris (Den norske lægeforening).
• 1996 Pris fra Overlege Dr. M.D. Johan Carl Unger Vetlesen Charitable Fund
• 2004 Ole Storsteins pris for 2004. Norsk Cardiologisk Selskap
• 2008  Fellow, European Society of Cardiology
• 2017  Fellow, American College of Cardiology

Verv

• 2016 Associate Editor, Circulation
• 2017 Editor of Chronic Coronary Artery Disease: A Companion to Braunwald’s Heart Disease, 1^stedition (Elsevier 2017). 
• 2017 Member, International Federation of Clinical Chemistry (IFCC) Task Force on Clinical Applications of Cardiac Bio-Markers
• 2017 Head, National Publication Committee for Medicine (NPU-MED), Norway
• 2017 Member National Publication Committee (NPU, Norway)
• 2017 Editorial Board, International Journal of Cardiology 
• 2017 Board member, Research Council, South-Eastern Regional Health Authority, Norway
• 2016  Board member, Norwegian Clinical Research Infrastructure Network (NorCRIN)
• Member of professor evaluation committees at the University of Oslo, Norway, University of Bergen, Norway, University of Aarhus, Denmark, University of Athens, Greece, University of Texas South-Western, Dallas, USA, Karolinska Institutet, Stockholm, Sweden
• Grant reviewer European Research Council, Canadian Institutes for Health Research (CIHR), Wellcome Trust, Swiss National Science Foundation, Foundation for Polish Science, Swedish Heart-Lung Foundation Big Award, North of Norway Regional Health Authority, Deutcshe Forschungsgemeinschaft (DFG)
• Reviewer in >30 international journals, including The New England Journal of Medicine, The Lancet, JAMA, Circulation, Journal of the American College of Cardiology, Nature Biotechnology

Samarbeid

• Professor Eugene Braunwald, TIMI Study Group, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; USA.
• Professor James A de Lemos, Dallas Heart Study, University of Texas Southwestern, Dallas, TX, USA.
• Professor Ramachandran Vasan, Framingham Heart Study, Framingham, MA
• Professor Kristian Hveem, Helseundersøkelsen i Nord-Trøndelag, NTNU, Trondheim

Veiledning

• Hovedveileder for 10 fullførte PhD grader
• Medveileder for 7 fullførte PhD grader
• Veileder for 13 medisinstudentoppgaver  

Utvalgte publikasjoner

1. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality following acute myocardial infarction.Circulation 1994;89:1573-1579. Times cited 328
2. Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DWT, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation1996;93:1963-1969. Times cited: 613
3. Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996;76:232-237. Times cited: 132
4. Tawakol A, Omland T, Gerhard M, Wu J, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation1997,95:1119-1121. Times cited: 607
5. de Lemos JA, Morrow DA, Bentley JH, Omland T, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-1021. Times cited: 949
6. Omland T, Persson, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide andlong-term mortality in acute coronary syndromes.Circulation 2002; 106:2913-2918.Times cited: 463
7. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Engl J Med 2002;347:161-167. Times cited: 2203.
8. Wang T, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and mortality. N Engl J Med 2004;350:655-663. Times cited: 954          
9. Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in chronic obstructive pulmonary disease. Eur Respir J 2007;29:279-283. Times cited: 177
10. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease. The PEACEt rial. J Am Coll Cardiol 2007;50:205-214. Times cited: 141
11. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, and Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008; (51) 6:627-633.Times cited: 151
12. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, and Braunwald E. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl JMed 2009; (361) 26:2538-2547. Times cited: 537
13. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, and McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; (304) 22:2503-2512. Times cited: 552
14. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Salytyte Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013;61:1240-1249. Times cited: 149
15. Omland T. Cardiac troponins: a tool for a personalized medicine strategy in stable coronary artery disease?  (Invited Editorial Comment) J Am Coll Cardiol 2014;63: 355-357.
16. Omland T, de Lemos JA, Holmen OL, Dalen H, Benth JS, Nygård S, Hveem K, Røsjø H. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population. Clin Chem 2015;61:646-656. Times cited: 30
17. Gulati G, Heck SL, Ree AH, Hoffman P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37: 1671-1680.Times cited: 77
18. Lyngbakken MN, Skranes JB, de Lemos JA, Nygård S, Dalen H, Hveem K, Røsjø H, Omland T. Impact of smoking on Circulating cardiac troponin I concentrations and cardiovascular events in the general population: The HUNT study (Nord-Trøndelag Health Study). Circulation 2016; 134: 1962-1972.
19. Omland T, Kullo IJ. Biomarker-based risk models to risk stratify patients with stable coronary heart disease. (Invited Editorial Comment) J Am Coll Cardiol 2017;70: 827-829.
20. Omland T.  Can Circulating BNP Concentrations Guide Treatment of Obstructive Left Main Coronary Artery Disease? (Invited Editorial Comment) Circulation 2018; 138:479-482.